The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
Attendance at the course counts as 7.5 hours towards any CPD requirements
Many thanks to GSK
for hosting the September event.
If you would like to host a PSI one day meeting for a topic of particular
interest to you please contact: nickm@amgen.com
(Scientific Chair) PSI
Upcoming Events
PSI Introduction to Industry Training (ITIT) Course - 2025/2026
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Urgent Meeting: Medical Statistician Apprenticeship Scheme
The UK government have recently announced that level 7 apprenticeships must be fully funded by the employer from January 2026, for any apprentice over the age of 21. With funding for MSc's at an all time low, and universities courses facing closures, the apprenticeship scheme remains as important as ever, as a tool to encourage new statisticians into our industry. In this dedicated meeting, Valerie Millar (chair of the apprenticeship scheme) will provide full updates on the government changes and seek feedback and ideas from employers, universities and apprentices on how to keep this scheme successfully running for many years to come.
PSI Webinar: Methodology and first results of the iRISE (improving Reproducibility In SciencE) consortium
This 1-hour webinar will be an opportunity to hear about the methodology and first results of the iRISE consortium. iRISE is working towards a better understanding of reproducibility and the interventions that work to improve it. At the end of the presentation there will also be the opportunity to ask questions.
One-day Event: Change Management for Moving to R/Open-Source
This one-day event focuses on the comprehensive management of transitioning to R/Open-Source, addressing the challenges and providing actionable insights. Attendees will participate in sessions covering essential topics such as training best practices, creating strategic plans, making the case to senior management, and managing both statistical and programming aspects of the transition.
PSI Book Club - The Art of Explanation: How to Communicate with Clarity and Confidence
Develop your non-technical skills by reading The Art of Explanation by Ros Atkins and joining the Sept-Dec 2025 book club. You will be invited to join facilitated discussions of the concepts and ideas and apply skills from the book in-between sessions.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
EFSPI/PSI Causal Inference SIG Webinar: Instrumental Variable Methods
The webinar is targeted at statisticians working in the pharmaceutical industry, and the objective is to 1) provide a basic understanding of IV methodology including how it relates to causal inference, and 2) present two inspirational pharma-relevant applications.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This is an exciting, new opportunity for an experienced Statistician looking to take the next step in their career. Offered as a remote or hybrid position aligned with our site in Harrogate, North Yorkshire.